{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:38:20Z","timestamp":1784039900659,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12325-022-02220-3","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T02:02:49Z","timestamp":1656554569000},"page":"3777-3788","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia\u00a0A in China"],"prefix":"10.1007","volume":"39","author":[{"given":"Congling","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-0785","authenticated-orcid":false,"given":"Yi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"2220_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.blre.2019.03.002","volume":"35","author":"B Samuelson Bannow","year":"2019","unstructured":"Samuelson Bannow B, Recht M, et al. Factor\u00a0VIII: long-established role in haemophilia\u00a0A and emerging evidence beyond haemostasis. Blood Rev. 2019;35:43\u201350.","journal-title":"Blood Rev"},{"issue":"Suppl 6","key":"2220_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"key":"2220_CR3","unstructured":"World Federation of Hemophilia. The WFH Report on the Annual Global Survey 2018-Hemophilia World News. https:\/\/news.wfh.org\/now-available-the-wfh-report-on-the-annual-global-survey-2018\/. Accessed 30 Mar 2020."},{"key":"2220_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/hae.14101","volume":"26","author":"X Dou","year":"2020","unstructured":"Dou X, Poon M-C, Yang R. Haemophilia care in China: achievements in the past decade. Haemophilia. 2020;26:759\u201367.","journal-title":"Haemophilia"},{"issue":"Suppl 5","key":"2220_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2516.2012.02890.x","volume":"18","author":"MC Ozelo","year":"2012","unstructured":"Ozelo MC, Matta MAP, Yang R. Meeting the challenges of haemophilia care and patient support in China and Brazil. Haemophilia. 2012;18(Suppl 5):33\u20138.","journal-title":"Haemophilia"},{"key":"2220_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/j.1365-2516.2009.02019.x","volume":"15","author":"A Miners","year":"2009","unstructured":"Miners A. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia\u00a0A. Haemophilia. 2009;15:881\u20137.","journal-title":"Haemophilia"},{"key":"2220_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/CEOR.S16670","volume":"3","author":"GL Colombo","year":"2011","unstructured":"Colombo GL, Di Matteo S, Mancuso ME, Santagostino E. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia\u00a0A. Clin Outcomes Res. 2011;3:55\u201361.","journal-title":"Clin Outcomes Res"},{"issue":"Suppl 3","key":"2220_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2516.2006.01268.x","volume":"12","author":"G Roosendaal","year":"2006","unstructured":"Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia. 2006;12(Suppl 3):117\u201321.","journal-title":"Haemophilia"},{"key":"2220_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535\u201344.","journal-title":"N Engl J Med"},{"key":"2220_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","volume":"232","author":"IM Nilsson","year":"1992","unstructured":"Nilsson IM, Berntorp E, L\u00f6fqvist T, Pettersson H. Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia\u00a0A and B. J Intern Med. 1992;232:25\u201332.","journal-title":"J Intern Med"},{"key":"2220_CR11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","volume":"9","author":"A Gringeri","year":"2011","unstructured":"Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia\u00a0A (the ESPRIT Study). J Thromb Haemost. 2011;9:700\u201310.","journal-title":"J Thromb Haemost"},{"key":"2220_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","volume":"65","author":"IM Nilsson","year":"1976","unstructured":"Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976;65:129\u201335.","journal-title":"Acta Paediatr Scand"},{"key":"2220_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1651-2227.1981.tb05741.x","volume":"70","author":"H Pettersson","year":"1981","unstructured":"Pettersson H, Nilsson IM, Hedner U, Nor\u00e9hn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand. 1981;70:565\u201370.","journal-title":"Acta Paediatr Scand"},{"key":"2220_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/j.1365-2516.2004.01036.x","volume":"10","author":"J Ahnstr\u00f6m","year":"2004","unstructured":"Ahnstr\u00f6m J, Berntorp E, Lindvall K, Bj\u00f6rkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10:689\u201397.","journal-title":"Haemophilia"},{"key":"2220_CR15","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1001\/archinte.1970.00310060082008","volume":"125","author":"CK Kasper","year":"1970","unstructured":"Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor\u00a0VIII concentrate. Arch Intern Med. 1970;125:1004\u20139.","journal-title":"Arch Intern Med"},{"key":"2220_CR16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-0609.1977.tb01528.x","volume":"30","author":"K Schimpf","year":"1977","unstructured":"Schimpf K, Fischer B, Rothmann P. Hemophilia\u00a0A prophylaxis with factor\u00a0VIII concentrate in a home-treatment program: a controlled study. Scand J Haematol Suppl. 1977;30:79\u201380.","journal-title":"Scand J Haematol Suppl"},{"key":"2220_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","volume":"8","author":"PW Collins","year":"2010","unstructured":"Collins PW, Bj\u00f6rkman S, Fischer K, et al. Factor\u00a0VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia\u00a0A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269\u201375.","journal-title":"J Thromb Haemost"},{"key":"2220_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/hae.13372","volume":"24","author":"Z Li","year":"2018","unstructured":"Li Z, Wu J, Zhao Y, Liu R, et al. Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia\u00a0A in China. Haemophilia. 2018;24:126\u201333.","journal-title":"Haemophilia"},{"key":"2220_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/hae.13071","volume":"23","author":"J Sun","year":"2017","unstructured":"Sun J, Zhao Y, Yang R, Guan T, Iorio A, Chinese HERO study group. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China\u2014results from the HERO study. Haemophilia. 2017;23:89\u201397.","journal-title":"Haemophilia"},{"key":"2220_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MBC.0000000000000610","volume":"28","author":"S Iannazzo","year":"2017","unstructured":"Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia\u00a0A. Blood Coagul Fibrinolysis. 2017;28:425\u201330.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2220_CR21","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/hae.13540","volume":"24","author":"ME Mingot-Castellano","year":"2018","unstructured":"Mingot-Castellano ME, Parra R, N\u00fa\u00f1ez R, Martorell M. Improvement in clinical outcomes and replacement factor\u00a0VIII use in patients with haemophilia\u00a0A after factor\u00a0VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT\u00ae. Haemophilia. 2018;24:e338\u201343.","journal-title":"Haemophilia"},{"key":"2220_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.thromres.2018.11.017","volume":"173","author":"A Nagao","year":"2019","unstructured":"Nagao A, Yeung CHT, Germini F, Suzuki T. Clinical outcomes in hemophilia\u00a0A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thromb Res. 2019;173:79\u201384.","journal-title":"Thromb Res"},{"key":"2220_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2019.08.022","volume":"183","author":"S Pasca","year":"2019","unstructured":"Pasca S, Zanon E. Savings without changing: how to use the MyPKfit\u00ae device to improve treatment strategies in a cohort of patients with haemophilia\u00a0A. Thromb Res. 2019;183:1\u20133.","journal-title":"Thromb Res"},{"key":"2220_CR24","unstructured":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association\/Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the treatment of hemophilia (version 2020). Chin J Hematol. 2020;41:265\u201371. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7364913\/. Accessed 11 Mar 2021."},{"key":"2220_CR25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16704","volume":"190","author":"R Rayment","year":"2020","unstructured":"Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia\u00a0A and B. Br J Haematol. 2020;190:684\u201395.","journal-title":"Br J Haematol"},{"key":"2220_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","volume":"119","author":"S Bj\u00f6rkman","year":"2012","unstructured":"Bj\u00f6rkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor\u00a0VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119:612\u20138.","journal-title":"Blood"},{"key":"2220_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","volume":"17","author":"IEM den Uijl","year":"2011","unstructured":"den Uijl IEM, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17:41\u20134.","journal-title":"Haemophilia"},{"key":"2220_CR28","first-page":"1590","volume":"32","author":"B Chen","year":"2019","unstructured":"Chen B, Xia A, Yu K. Determination of pharmacokinetic parameters in adult patients with severe hemophilia\u00a0A and the efficacy of individualized preventive treatment. J Math Med. 2019;32:1590\u20132.","journal-title":"J Math Med"},{"key":"2220_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jval.2012.05.005","volume":"15","author":"EJ Neufeld","year":"2012","unstructured":"Neufeld EJ, Recht M, Sabio H, et al. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. Value Health. 2012;15:916\u201325.","journal-title":"Value Health"},{"key":"2220_CR30","unstructured":"Yaozhi.com drug bidding information query-Baiyinzhi. https:\/\/db.yaozh.com\/yaopinzhongbiao?comprehensivesearchcontent=%E7%99%BE%E5%9B%A0%E6%AD%A2&. Accessed 23 Mar 2021."},{"issue":"Suppl 1","key":"2220_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jth.15189","volume":"19","author":"CRM Hay","year":"2021","unstructured":"Hay CRM, Nissen F, Pipe SW. Mortality in congenital hemophilia\u00a0A\u2014a systematic literature review. J Thromb Haemost. 2021;19(Suppl 1):6\u201320.","journal-title":"J Thromb Haemost"},{"key":"2220_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/hae.12480","volume":"20","author":"A Iorio","year":"2014","unstructured":"Iorio A, Marcucci M, Cheng J, et al. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia\u00a0A patients treated with rAHF-PFM. Haemophilia. 2014;20:777\u201383.","journal-title":"Haemophilia"},{"key":"2220_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/hae.12079","volume":"19","author":"LH Schrijvers","year":"2013","unstructured":"Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K. Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia. 2013;19:355\u201361.","journal-title":"Haemophilia"},{"key":"2220_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.thromres.2018.12.027","volume":"174","author":"JE Meg\u00edas-Vericat","year":"2019","unstructured":"Meg\u00edas-Vericat JE, Bonanad S, Haya S, et al. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor\u00a0VIII in severe or moderate haemophilia\u00a0A. Thromb Res. 2019;174:151\u201362.","journal-title":"Thromb Res"},{"key":"2220_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/00019053-200523040-00003","volume":"23","author":"JJ Caro","year":"2005","unstructured":"Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23:323\u201332.","journal-title":"Pharmacoeconomics"},{"key":"2220_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40273-014-0147-9","volume":"32","author":"J Karnon","year":"2014","unstructured":"Karnon J, Haji Ali Afzali H. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics. 2014;32:547\u201358.","journal-title":"Pharmacoeconomics"},{"key":"2220_CR37","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1524-4733.2010.00775.x","volume":"13","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, M\u00f6ller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13:1056\u201360.","journal-title":"Value Health"},{"key":"2220_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00019053-200927020-00006","volume":"27","author":"KN Simpson","year":"2009","unstructured":"Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009;27:159\u201365.","journal-title":"Pharmacoeconomics"},{"key":"2220_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.thromres.2017.07.003","volume":"157","author":"S Pasca","year":"2017","unstructured":"Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia\u00a0A. Thromb Res. 2017;157:58\u201363.","journal-title":"Thromb Res"},{"key":"2220_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ped4.12122","volume":"3","author":"P Li","year":"2019","unstructured":"Li P, Chen Z, Cheng X, et al. PK-tailored tertiary prophylaxis in patients with severe hemophilia\u00a0A at Beijing Children\u2019s Hospital. Pediatr Investig. 2019;3:45\u20139.","journal-title":"Pediatr Investig"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02220-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02220-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T22:57:56Z","timestamp":1700780276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02220-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2220"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02220-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}